Zenas BioPharma Q1 EPS Forecast Lowered by HC Wainwright

Zenas BioPharma, Inc. (NASDAQ:ZBIO) – HC Wainwright lowered their Q1 2026 earnings estimates for Zenas BioPharma in a report issued on Tuesday, March 17th. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($1.30) per share for the quarter, down from their previous estimate of ($1.06). HC Wainwright currently has a “Buy” rating and a $44.00 target price on the stock. HC Wainwright also issued estimates for Zenas BioPharma’s Q2 2026 earnings at ($1.29) EPS, Q3 2026 earnings at ($1.28) EPS, Q4 2026 earnings at ($0.55) EPS, FY2026 earnings at ($4.39) EPS, FY2027 earnings at ($3.67) EPS, FY2028 earnings at ($3.26) EPS, FY2029 earnings at ($2.62) EPS and FY2030 earnings at ($1.38) EPS.

Zenas BioPharma (NASDAQ:ZBIO) last announced its quarterly earnings data on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

ZBIO has been the topic of a number of other research reports. Evercore assumed coverage on Zenas BioPharma in a research report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price objective on the stock. Zacks Research lowered Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Tuesday. Jefferies Financial Group reissued a “buy” rating and set a $48.00 target price on shares of Zenas BioPharma in a research note on Tuesday, January 6th. Morgan Stanley upped their price target on Zenas BioPharma from $19.00 to $21.00 and gave the stock an “equal weight” rating in a report on Tuesday. Finally, Guggenheim increased their price target on Zenas BioPharma from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $44.14.

Zenas BioPharma Price Performance

Zenas BioPharma stock opened at $23.37 on Thursday. The company has a quick ratio of 5.66, a current ratio of 5.61 and a debt-to-equity ratio of 0.32. Zenas BioPharma has a 52-week low of $6.11 and a 52-week high of $44.60. The firm has a market cap of $1.34 billion, a PE ratio of -2.99 and a beta of -1.94. The company’s 50 day moving average is $23.05 and its two-hundred day moving average is $27.12.

Institutional Trading of Zenas BioPharma

A number of institutional investors have recently bought and sold shares of ZBIO. Federated Hermes Inc. boosted its position in shares of Zenas BioPharma by 60.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after acquiring an additional 703,838 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Zenas BioPharma by 41.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock worth $89,000 after acquiring an additional 2,679 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Zenas BioPharma during the fourth quarter worth approximately $227,000. Sei Investments Co. purchased a new stake in Zenas BioPharma during the second quarter worth approximately $118,000. Finally, BNP Paribas Financial Markets boosted its holdings in Zenas BioPharma by 120.0% in the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after purchasing an additional 1,716 shares in the last quarter.

Insider Buying and Selling at Zenas BioPharma

In other news, Director Patricia L. Allen acquired 4,160 shares of Zenas BioPharma stock in a transaction dated Friday, February 13th. The shares were acquired at an average cost of $26.36 per share, for a total transaction of $109,657.60. Following the acquisition, the director owned 19,860 shares of the company’s stock, valued at $523,509.60. This trade represents a 26.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Leon O. Moulder, Jr. acquired 57,000 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were purchased at an average cost of $17.96 per share, with a total value of $1,023,720.00. Following the completion of the transaction, the chief executive officer owned 423,155 shares in the company, valued at approximately $7,599,863.80. The trade was a 15.57% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have bought 202,845 shares of company stock valued at $3,747,185. Insiders own 16.50% of the company’s stock.

Trending Headlines about Zenas BioPharma

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and maintained a $44 price target on Zenas BioPharma — a bullish anchor that can support demand even as the firm revised estimates. HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO)
• Neutral Sentiment: Technical/background context: the stock is trading near its 50-day moving average with below-average volume and remains well off its 52‑week high — trading dynamics that can amplify the impact of analyst notes. Zenas BioPharma (ZBIO) Market Data
• Negative Sentiment: Zacks Research downgraded Zenas from “Hold” to “Strong Sell,” a clear negative signal that can pressure sentiment and attract short‑term selling. Zacks.com
• Negative Sentiment: HC Wainwright significantly lowered EPS forecasts across Q1–Q4 2026 and multiple outyears (FY2026–FY2030), cutting FY2026 and subsequent year estimates materially — this weakens near‑term fundamentals despite the Buy rating. Zenas BioPharma analyst estimate updates
• Negative Sentiment: Citigroup lowered its price target to $41, another downward revision to modeled upside that could cap gains if other analysts follow suit. Zenas BioPharma (NASDAQ:ZBIO) Price Target Cut to $41.00 by Analysts at Citigroup

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.